Switzerland's MoonLake Q3 net loss widens as R&D costs rise
MLTX•MoonLake reported a Q3 net loss of $79.55 million, or $0.93 per share, as R&D expenses rose. It ended the quarter with $498.5 million in cash and expects its runway to extend to mid-2028.
1. Quarterly results
MoonLake reported a Q3 net loss of $79.55 million, or $0.93 per share. R&D expenses increased mainly because of milestone license fees tied to a regulatory milestone associated with the expected acceptance of its BLA submission.
2. Sonelokimab outlook
MoonLake submitted a Biologics License Application for sonelokimab to the FDA for hidradenitis suppurativa. The company expects a decision on whether the FDA will accept the filing by the end of November 2026 and anticipates a potential U.S. commercial launch in the second half of 2027, if approved.
3. Cash position
MoonLake ended Q3 with $498.5 million in cash and expects its cash runway to extend to mid-2028.
